Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2001 December;26(4) > Minerva Endocrinologica 2001 December;26(4):225-30

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

  NEW DIAGNOSTIC AND THERAPEUTIC STRATEGIES: SOMATOSTATIN ANALOGS. Part II 

Minerva Endocrinologica 2001 December;26(4):225-30

Copyright © 2001 EDIZIONI MINERVA MEDICA

language: Italian

Somatostatin analogues for treatment of gastroenteropancreatic neuroendocrine tumours

Uomo G., Germano D., Rabitti P. G.


PDF


Somatostatin has represented a significant breakthrough in the treatment of patients with hormone-acting, neuroendocrine gastro-intestinal-pancreatic (NEGEP) neoplasms, even if its short half-life made it impractical in the clinical practice. Over the last recent years new long-acting formulations have been developed from the native peptide. Octreotide, lanreotide and vapeotide are octapeptides with similar biological activity, remarkable stability and longer half-life; an extended-release formulation of octreotide (Octreotide-LAR) and lanreotide (Lanreotide-SR) have been more recently developed by incorporating the peptide in microspheres of a biodegradable polymer. This formulation was conceived to provide patients with the convenience of a once-a-month or twice-a-month injection and to ensure a stable serum concentration between injections and good clinical control of NEGEP tumours symptoms. Nowadays, somatostatin long-acting analogues represent the first treatment option in those patients who doesn't underwent radical surgery; in addition, these substances present no important side effects, ameliorate the prognosis and can exert some degree of tumour growth control.

top of page